var data={"title":"Gentamicin (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gentamicin (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389790?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gentamicin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gentamicin (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=gentamicin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Gentamicin (systemic): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107079\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ensure that patients treated with aminoglycosides are under close clinical observation because of the potential toxicity associated with their use.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">As with other aminoglycosides, gentamicin is potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high dosages or prolonged therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neurotoxicity, manifested by ototoxicity, both vestibular and auditory, can occur in patients treated with gentamicin, primarily in those with preexisting renal damage and in patients with healthy renal function treated with higher doses and/or for longer periods than recommended. Aminoglycoside-induced ototoxicity is usually irreversible. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Closely monitor renal and eighth cranial nerve functions, especially in patients with known or suspected reduced renal function at onset of therapy, and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Examine urine for decreased specific gravity, increased excretion of protein, and the presence of cells or casts. Periodically determine serum urea nitrogen (BUN), serum creatinine, or creatinine clearance (CrCl). When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears, or hearing loss) or nephrotoxicity requires dosage adjustment or discontinuance of the drug. As with the other aminoglycosides, on rare occasions, changes in renal and eighth cranial nerve function may not manifest until soon after completion of therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor serum concentrations of aminoglycosides when feasible to ensure adequate levels and to avoid potentially toxic levels. When monitoring gentamicin peak concentrations, adjust dosage so that prolonged levels above 12 mcg/mL are avoided. When monitoring gentamicin trough concentrations, adjust dosage so that levels above 2 mcg/mL are avoided. Excessive peak or trough serum concentrations of aminoglycosides may increase the risk of renal and eighth cranial nerve toxicity. In the event of overdose or toxic reactions, hemodialysis may aid in the removal of gentamicin from the blood, especially if renal function is, or becomes, compromised. The rate of removal of gentamicin is considerably less by peritoneal dialysis than by hemodialysis.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Avoid concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin. Other factors that may increase patient risk of toxicity are advanced age and dehydration.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Avoid the concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously (IV), diuretics may enhance aminoglycoside toxicity by altering the antibiotic concentration in serum and tissue.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides can cause fetal harm when administered to a pregnant woman.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107109\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Gentamicin Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107344\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Aminoglycoside</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107267\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>In underweight and nonobese patients, use of total body weight (TBW) instead of ideal body weight for determining the initial mg/kg/dose is widely accepted (Nicolau 1995). Ideal body weight (IBW) also may be used to determine doses for patients who are neither underweight nor obese (Gilbert 2009). </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Initial and periodic plasma drug levels (eg, peak and trough with conventional dosing, post dose level at a prespecified time with extended-interval dosing) should be determined, particularly in critically-ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Usual dosage ranges:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conventional: IM, IV: 3 to 5 mg/kg/day in divided doses every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Once daily (extended-interval dosing [EID]): IV: 5 to 7 mg/kg/day once daily; not recommended in patients with ascites, burns covering &gt;20% of the total body surface area, cystic fibrosis, end-stage renal disease (eg, requiring hemodialysis), endocarditis, infants, mycobacterial infections, or pregnancy (Bailey 1997; Nicolau 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Brucellosis (off-label use):</b> 5 mg/kg once daily for 7 days (range: 5 to 14 days); administered in combination with 6 weeks of doxycycline (Ariza 2007). Additional data may be necessary to further define the role of gentamicin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cerebrospinal fluid (CSF) shunt infection (off-label route):</b> Intraventricular (use a preservative-free preparation): 4 to 8 mg/day (IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment </b>(AHA [Baddour 2015])<b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enterococcus</i> (native or prosthetic valve) (off-label dose): IV, IM: 3 mg/kg/day in 2 or 3 divided doses in combination with a beta-lactam or vancomycin (choice of concomitant antibiotic and treatment duration are dependent on organism sensitivity testing and source of infection)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus</i> (prosthetic valve; methicillin-susceptible or methicillin-resistant) (off-label dose): IV, IM: 3 mg/kg/day in 2 or 3 divided doses for 2 weeks; use in combination with other antibiotics (choice of concomitant antibiotic dependent on organism sensitivity testing)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Viridans group streptococcus (VGS) and <i>S. bovis</i> (native or prosthetic valve) (off-label use): IV, IM: 3 mg/kg/day once daily (preferred) or in 3 divided doses (alternative) in combination with other antibiotics (choice of concomitant antibiotic and treatment duration are dependent on organism sensitivity testing and source of infection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonococcal infection, uncomplicated (patients with severe cephalosporin allergy) (off-label use):</b> IM: 240 mg as a single dose in combination with oral azithromycin (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Granuloma inguinale (donovanosis) (off-label use):</b> 1 mg/kg/dose every 8 hours; gentamicin must be used in addition to the recommended antibiotic agent and only if improvement is not evident within the first days of therapy (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis due to </b>\n      <b>\n        <i>Enterococcus </i></b> <b>spp (off-label use), </b><b><i> Listeria monocytogenes </i></b> <b>(off-label use), </b><b><i>Streptococcus agalactiae </i></b> <b>(off-label use), or </b><b><i>Pseudomonas aeruginosa:</i></b> IV: 5 mg/kg/day in divided doses every 8 hours (administered with other antimicrobials [varies by causative organism and susceptibility]) (IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infections (off-label dose):</b> IV: 5 to 7 mg/kg once daily for 4 to 7 days (unless it is difficult to achieve source control) (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic inflammatory disease (off-label):</b> Loading dose: 2 mg/kg IV or IM, then 1.5 mg/kg IV every 8 hours or 3 to 5 mg/kg IV once daily in combination with clindamycin IV. Transition from parenteral to oral therapy can usually be initiated within 24 to 48 hours of clinical improvement for a total treatment duration of 14 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritoneal dialysis-associated peritonitis (off-label use) (ISPD [Li 2016]):</b> Intraperitoneal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent dosing: 0.6 mg/kg per exchange once daily; allow to dwell &ge;6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous dosing (all exchanges): Loading dose: 8 mg/<b>L</b>; maintenance dose: 4 mg/<b>L</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plague </b>\n      <b>(<i>Yersinia pestis</i>), treatment (off-label use):</b> 5 mg/kg/dose once daily <b>or</b> 2 mg/kg loading dose, then 1.7 mg/kg/dose every 8 hours; duration of therapy is 10 to 14 days, or until 2 days after patient is afebrile (CDC 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, hospital-acquired or ventilator-associated (off-label):</b> IV: 5 to 7 mg/kg/day once daily for 7 days; may consider shorter or longer duration depending on rate of clinical improvement. When used as empiric therapy, use in combination with an agent active against <i>S. aureus</i> and an additional antipseudomonal agent. <b>Note:</b> Aminoglycosides are not recommended as monotherapy in patients with hospital-acquired or ventilator-associated pneumonia due to <i>P. aeruginosa</i> (Kalil 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sepsis/septic shock (empiric or targeted therapy) (off-label):</b> IV: 5 to 7 mg/kg once daily; first dose administered as soon as possible and within 1 hour of identifying sepsis/septic shock. A duration of therapy of 7 to 10 days is generally adequate for serious infections; a variety of factors play a role in determining optimal duration of therapy; infectious diseases consultation may be necessary (SSC [Rhodes 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical (preoperative) prophylaxis (off-label use):</b> IV: 5 mg/kg within 60 minutes prior to surgical incision with or without other antibiotics (procedure dependent). <b>Note:</b> Dose is based on actual body weight unless &gt;20% above ideal body weight, then dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW) (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Synergy (for gram-positive infections):</b> 3 mg/kg/day in 1-3 divided doses (with ampicillin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tularemia (off-label use):</b> 5 mg/kg/dose once daily for 10 days (Dennis 2001) or 5 mg/kg/day in 2 divided doses for &ge;10 days (WHO 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107266\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=gentamicin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Gentamicin (systemic): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage should be based on an estimate of ideal body weight. In morbidly obese children and adolescents, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW). Dosage should be individualized based upon serum concentration monitoring. Initial and periodic plasma drug concentrations (eg, peak and trough with conventional dosing, post dose level at a prespecified time with extended-interval dosing) should be determined, particularly in critically ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery). Some dosing based on gentamicin studies:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conventional dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IM, IV: 2.5 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: IM, IV: 2 to 2.5 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Infants, Children, and Adolescents: IM, IV: 2 to 2.5 mg/kg/dose every 8 hours; some pediatric patients may require larger doses (ie, patients undergoing continuous hemofiltration, patients with major burns, febrile granulocytopenic patients); modify dose based on individual patient requirements as determined by renal function, serum drug concentrations, and patient-specific clinical parameters (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-interval dosing:</i> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed: Infants, Children, and Adolescents: IV: 4.5 to 7.5 mg/kg/dose every 24 hours in patients with normal renal function (Contopoulos-Ioannidis 2004; <i>Red Book</i> (AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Age-directed: Based on data from 114 patients, the following has been suggested (McDade 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &ge;3 months to &lt;2 years: IV: 9.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to &lt;8 years: IV: 8.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;8 years and Adolescents: IV: 7 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Synergy dosing (off-label dose): Children and Adolescents: IV: 3 to 6 mg/kg/<b>day</b> divided every 8 hours in combination with other antibiotics; adjust dose to achieve a target peak concentration of 3 to 4 mcg/mL and trough concentration &lt;1 mcg/mL (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>S. aureus</i> (methicillin-resistant), prosthetic valve/material (off-label dose): Infants, Children, and Adolescents: IV: 3 mg/kg/<b>day</b> divided every 8 hours in combination with vancomycin and rifampin (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment dose (eg, gram negative organisms): Children and Adolescents: IV: 7.5 mg/kg/<b>day</b> divided every 8 hours; adjust to achieve a target peak concentration of 5 to 10 mcg/L and trough concentration &lt;1 to 1.5 mcg/mL (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Surgical (preoperative) prophylaxis (off-label use):</b> Infants, Children, and Adolescents: IV: 2 to 2.5 mg/kg as a single dose; in children and adolescents, a dose of 2.5 mg/kg is typically suggested; administer within 60 minutes prior to surgical incision with or without other antibiotics (procedure dependent) (Bratzler 2013; <i>Red Book</i> [AAP 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107268\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107269\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adults:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conventional dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: Administer usual dosage for initial dose, then estimate reduced dose by dividing initial dose by patient&rsquo;s serum creatinine level (in mg/dL) and administer every 8 hours (eg, a 60 kg patient with serum creatinine of 2 mg/dL at a dose of 1 mg/kg would receive an initial dose of 60 mg, followed by 30 mg every 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 1.7 mg/kg/dose every 8 hours or 5 to 7 mg/kg/dose once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 50 mL/minute: Administer every 12 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute: Administer every 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Once daily (extended-interval dosing [EID]) (Bailey 1997; Nicolau 1995): <b>Note:</b> Base initial dosing interval on the following; adjust interval based on serum levels using institution-specific policies.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: Administer every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 59 mL/minute: Administer every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 39 mL/minute: Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute: Monitor serum levels and redose when gentamicin level is less than 1 mcg/mL or use conventional dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> In patients with sepsis/septic shock and severe renal impairment, the SSC guidelines do not recommend use of once-daily dosing. Patients with mild renal impairment should still receive once-daily dosing with an extended interval (ie, up to 3 days) (SSC [Rhodes 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days) (Heintz 2009): Dialyzable (~50%; variable; dependent on filter, duration, and type of IHD):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose of 2 to 3 mg/kg loading dose followed by:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild UTI or synergy: 1 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD or post-HD concentrations &lt;1 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate-to-severe UTI: 1 to 1.5 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD concentrations &lt;1.5 to 2 mg/L or post-HD concentrations &lt;1 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Systemic gram-negative rod infection: 1.5 to 2 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD concentrations &lt;3 to 5 mg/L or post-HD concentrations &lt;2 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as target drug concentrations (if appropriate). <b>Note:</b> The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVH/CVVHD/CVVHDF:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild UTI or synergy: Loading dose of 2 to 3 mg/kg/dose followed by 1 mg/kg every 24 to 36 hours (redose when concentration &lt;1 mg/L [Heintz 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe UTI: Loading dose of 2 to 3 mg/kg/dose followed by 1 to 1.5 mg/kg every 24 to 36 hours (redose when concentration &lt;1.5 to 2 mg/L [Heintz 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Systemic gram-negative infection: Loading dose of 2 to 3 mg/kg/dose followed by 1.5 to 2.5 mg/kg every 24 to 48 hours (generally accepted to redose when concentration &lt;2 mg/L; one reference suggests redosing when &lt;3 mg/L [Heintz 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Infants, Children, and Adolescents:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conventional dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following adjustments have been recommended (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 2.5 mg/kg/dose every 8 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer every 12 to 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer every 18 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer every 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD): 2 mg/kg/dose; redose as indicated by serum concentration</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): 2 mg/kg/dose; redose as indicated by serum concentration</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): 2 to 2.5 mg/kg/dose every 12 to 24 hours, monitor serum concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107270\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however dosage adjustment is not likely to be necessary (does not undergo hepatic metabolism).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330558\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">In moderate obesity (TBW/IBW &ge;1.25) or greater (eg, morbid obesity [TBW/IBW &gt;2]), initial dosage requirement may be estimated using a dosing weight of IBW + 0.4 (TBW - IBW) (Traynor 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107316\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (2 mL); 40 mg/mL (2 mL, 20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg (50 mL); 70 mg (50 mL [DSC]); 80 mg (50 mL, 100 mL); 90 mg (100 mL [DSC]); 100 mg (50 mL, 100 mL); 120 mg (100 mL); 10 mg/mL (6 mL [DSC], 8 mL [DSC], 10 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107117\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107276\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer by deep IM route if possible.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 30 to 120 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides  in vitro. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy in vivo, particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107118\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Serious infections: </b>Treatment of serious infections (eg, sepsis, meningitis, urinary tract infections, respiratory tract infections, peritonitis, bone infections, skin and soft tissue infections) caused by susceptible strains of the following microorganisms: <i>P. aeruginosa</i>, <i>Proteus</i> species (indole-positive and indole-negative), <i>Escherichia coli</i>, <i>Klebsiella</i> species, <i>Enterobacter</i> species, <i>Serratia</i> species, <i>Citrobacter</i> species, and <i>Staphylococcus</i> species (coagulase-positive and coagulase-negative); treatment of infective endocarditis caused by enterococci, in combination with other antibiotics.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475908\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Brucellosis; Endocarditis, treatment (viridans group streptococcus [VGS] and S. bovis [native or prosthetic valve]) (adults); Gonococcal infection, uncomplicated (patients with severe cephalosporin allergy); Granuloma inguinale (donovanosis); Meningitis due to Enterococcus spp, Listeria monocytogenes, or Streptococcus agalactiae; Pelvic inflammatory disease; Peritoneal dialysis-associated peritonitis; Plague, treatment; Surgical prophylaxis (preoperative); Tularemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107082\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Gentamicin may be confused with gentian violet, kanamycin, vancomycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107169\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, hypertension, hypotension, phlebitis, thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, ataxia, brain disease, confusion, depression, dizziness, drowsiness, headache, lethargy, myasthenia, numbness, paresthesia, peripheral neuropathy, pseudomotor cerebri, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, erythema, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, <i>Clostridium difficile-</i>associated diarrhea, decreased appetite, enterocolitis, nausea, sialorrhea, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Casts in urine (hyaline, granular), Fanconi-like syndrome (infants and adults; high dose, prolonged course), oliguria, proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, eosinophilia, granulocytopenia, leukopenia, purpura, reticulocytopenia, reticulocytosis, splenomegaly, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatomegaly, increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, anaphylactoid reaction, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, muscle cramps, muscle fatigue (myasthenia gravis-like syndrome), muscle twitching, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auditory impairment, hearing loss (associated with persistently increased serum concentrations; early toxicity usually affects high-pitched sound), tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Decreased creatinine clearance, decreased urine specific gravity, increased blood urea nitrogen, increased serum creatinine, polyuria, renal failure (high trough serum concentrations), renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, laryngeal edema, pulmonary fibrosis, respiratory depression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107166\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gentamicin, other aminoglycosides, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107167\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Cross-sensitivity to other aminoglycosides may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity:<b> [US Boxed Warning]: May cause nephrotoxicity;</b> usual risk factors include preexisting renal impairment, concomitant nephrotoxic medications, advanced age and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular blockade and respiratory paralysis: May cause neuromuscular blockade and respiratory paralysis; especially when given soon after anesthesia or neuromuscular blockers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity; </b>usual risk factors include preexisting renal impairment, concomitant neuro-/nephrotoxic medications, advanced age and dehydration. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage.  Discontinue treatment if signs of ototoxicity occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i> Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte abnormalities: Use with caution in patients with hypocalcemia, hypokalemia, or hypomagnesemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with pre-existing renal insufficiency; dosage modification required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy:<b> [US Boxed Warning]: Aminoglycosides may cause fetal harm if administered to a pregnant woman.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxic and/or nephrotoxic drugs:<b> [US Boxed Warning]: Avoid concomitant or sequential use of other neurotoxic and/or nephrotoxic drugs (eg, cisplatin, polymyxin B, colistin, vancomycin, other aminoglycosides).</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Potent diuretics: <b>[US Boxed Warning]: Avoid concomitant use with potent diuretics (eg, ethacrynic acid, furosemide) since diuretics themselves may cause ototoxicity and may enhance aminoglycoside toxicity.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-term use: Risk of toxicity is increased with extended duration of administration; additional monitoring may be required with long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical irrigation: May be almost completely systemically absorbed after local irrigation and/or topical application (except to the urinary bladder) during surgical procedures. Consider potential for nephrotoxicity, neuromuscular blockade, ototoxicity, and respiratory paralysis when administering aminoglycosides in this manner.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299397\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107194\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9142&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agalsidase Alfa: Gentamicin (Systemic) may diminish the therapeutic effect of Agalsidase Alfa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agalsidase Beta: Gentamicin (Systemic) may diminish the therapeutic effect of Agalsidase Beta. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<b> Exceptions: </b>Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107119\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107120\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Aminoglycosides may cause fetal harm if administered to a pregnant woman.</b> Gentamicin crosses the placenta. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of gentamicin may be altered (Popovi&#263; 2007). Gentamicin use has been evaluated for various infections in pregnant women including the treatment of acute pyelonephritis (Jolley 2010) and as an alternative antibiotic for prophylactic use prior to cesarean delivery (Bratzler 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107165\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Gentamicin is found in breast milk (Celiloglu 1994).  As a class, aminoglycosides are expected to be poorly distributed into breast milk, limiting systemic exposure to a nursing infant. In general, modification of bowel flora may occur with any antibiotic exposure (Chung 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107280\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinalysis, urine output, BUN, serum creatinine, plasma gentamicin levels (as appropriate to dosing method). Levels are typically obtained before and after the third dose in conventional dosing. Hearing should be tested before, during, and after treatment; particularly in those at risk for ototoxicity or who will be receiving prolonged therapy (&gt;2 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some penicillin derivatives may accelerate the degradation of aminoglycosides in vitro. This may be clinically-significant for certain penicillin (ticarcillin, piperacillin, carbenicillin) and aminoglycoside (gentamicin, tobramycin) combination therapy in patients with significant renal impairment. Close monitoring of aminoglycoside levels is warranted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107222\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conventional dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Timing of serum samples: Draw peak 30 minutes after 30-minute infusion has been completed or 1 hour after IM injection; draw trough immediately before next dose is due</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Therapeutic levels:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sepsis, pneumonia, other serious infections: 6 to 8 mcg/mL (Matzke 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Life-threatening infections: 8 to 10 mcg/mL (Zaske 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Urinary tract infections, including pyelonephritis: 4 to 6 mcg/mL (Matzke 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Synergy against gram-positive organisms: 3 to 4 mcg/mL (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Trough:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serious infections: 0.5 to 1 mcg/mL (Zaske 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Life-threatening infections: 1 to 2 mcg/mL (Zaske 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Synergy against gram-positive organisms: &lt;1 mcg/mL (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Obtain drug levels after the third dose unless renal dysfunction/toxicity suspected</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Once daily (Extended-interval dosing [EID]): Obtain a random gentamicin level between 6 and 14 hours after the start of the gentamicin infusion. Refer to institution-specific nomogram/policies to determine appropriate dosing interval. When therapy is continued for 5 days or more, monitor the gentamicin level once or twice weekly (Bailey 1997; Nicolau 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intraventricular therapeutic drug monitoring: Prior to administration of the next intraventricular dose, withdraw a sample of CSF. This trough CSF concentration divided by the gentamicin MIC of the isolated bacterial pathogen (inhibitory quotient) should exceed 10 to 20 (IDSA [Tunkel 2004]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107220\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit resulting in a defective bacterial cell membrane</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107223\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Intramuscular: Rapid and complete; Oral: Poorly absorbed (&lt;1%) (MacDougall 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Primarily into extracellular fluid (highly hydrophilic); high concentration in the renal cortex; minimal penetration to CSF and ocular tissues via IV route</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>: Higher in neonates than older pediatric patients; increased by edema, ascites, fluid overload; decreased with dehydration</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates: 0.45 &plusmn; 0.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 0.4 &plusmn; 0.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 0.35 &plusmn; 0.15 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 0.3 &plusmn; 0.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 0.2 to 0.3 L/kg (Leggett 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CSF:blood level ratio: Normal meninges: &lt;10%; Inflamed meninges: &le;25% (MacDougall 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: &lt;1 week: 3 to 11.5 hours; 1 week to 1 month: 3 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 4 &plusmn; 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 2 &plusmn; 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: 1.5 &plusmn; 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~2 hours (Regamey 1973); Renal failure: mean: 41 &plusmn; 24 hours; Range: 6 to 127 hours (Dager 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 30 to 90 minutes; IV: 30 minutes after 30-minute infusion (MacDougall 2011); <b>Note:</b> Distribution may be prolonged after larger doses. One study reported a 1.7-hour distribution period after a 60-minute, high-dose aminoglycoside infusion (Demczar 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&ge;70% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Directly related to renal function</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates: 0.045 &plusmn; 0.01 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 0.1 &plusmn; 0.05 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 0.1 &plusmn; 0.03 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 0.09 &plusmn; 0.03 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107318\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gentamicin Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (2 mL): $2.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (2 mL): $1.06</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12707701\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agentam (PH);</li>\n      <li>Alcomicin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Apigent (AE, BH, CY, EG, IQ, IR, JO, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Azupel (PY);</li>\n      <li>Bacticid (LK);</li>\n      <li>Balticin (ID);</li>\n      <li>Biogaracin (IN);</li>\n      <li>Cidomycin (AE, BH, CY, EG, GB, IE, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE, ZA);</li>\n      <li>Diakarmon (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Epigent (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Ethigent (ID);</li>\n      <li>Evozar (BR);</li>\n      <li>Gamicin (TW);</li>\n      <li>Gantalyn (CL);</li>\n      <li>Garalone (PT);</li>\n      <li>Garamicin (TH);</li>\n      <li>Garamicina (BR, CO, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Garamycin (AE, BH, CH, CY, CZ, EG, HK, HR, ID, IN, IQ, IR, JO, KW, LB, LY, NL, OM, PL, QA, RU, SA, SE, SG, SY, TH, TR, TW, YE);</li>\n      <li>Garasent (MY, SG);</li>\n      <li>Garasone (CZ);</li>\n      <li>Garaxil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gem (LK);</li>\n      <li>Gemycin (JO);</li>\n      <li>Genacin (PK);</li>\n      <li>Genbexil (EC);</li>\n      <li>Genmisil (VN);</li>\n      <li>Genoptic (AU, BH, CY);</li>\n      <li>Gensumycin (FI, NO, SE);</li>\n      <li>Genta-590 (PE);</li>\n      <li>Gentabiotic (PE);</li>\n      <li>Gentabrand (EC);</li>\n      <li>Gentac (TW);</li>\n      <li>Gentacare (PH);</li>\n      <li>Gentaderm (AR);</li>\n      <li>Gentagram (BR, PE);</li>\n      <li>Gental (PY, TH);</li>\n      <li>Gentalline (FR);</li>\n      <li>Gentalyn (IT, PE, VE);</li>\n      <li>Gentam (KW, QA, SA);</li>\n      <li>Gentamax (EC);</li>\n      <li>Gentamed (CY, JO);</li>\n      <li>Gentamen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Gentamina (AR, PY);</li>\n      <li>Gentamytrex (NL);</li>\n      <li>Gentapro (KR, SG);</li>\n      <li>Gentarad (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Gentasil (PE);</li>\n      <li>Gentasporin (IN);</li>\n      <li>Gentatrim (IL);</li>\n      <li>Gentawin (TH);</li>\n      <li>Genticin (AE, BF, BH, BJ, CI, CY, EG, ET, GB, GH, GM, GN, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TR, TZ, UG, YE, ZM, ZW);</li>\n      <li>Genticyn (IN);</li>\n      <li>Gentocil (PT);</li>\n      <li>Hexamycin (DK);</li>\n      <li>Ikagen (ID);</li>\n      <li>Intagenta (ET);</li>\n      <li>Jie Li Tai (CN);</li>\n      <li>Lacromycin (IL);</li>\n      <li>Lyramycin (IN);</li>\n      <li>Maxigen (PH);</li>\n      <li>Miragenta (CO);</li>\n      <li>Miramycin (HK, SG, TH);</li>\n      <li>Mycin (LK, PH);</li>\n      <li>Nelgen (PH);</li>\n      <li>Obogen (PH);</li>\n      <li>Ophtagram (BE);</li>\n      <li>Optimycin (BF, BJ, CI);</li>\n      <li>Provisual (AR);</li>\n      <li>Qutacin (TW);</li>\n      <li>Refobacin (AT, DE);</li>\n      <li>Rigaminol (PE);</li>\n      <li>Rocy Gen (PH);</li>\n      <li>Rovixida (AR);</li>\n      <li>Rupegen (AR);</li>\n      <li>Servigenta (MY);</li>\n      <li>Sulmycin (DE);</li>\n      <li>Versigen (TH);</li>\n      <li>Vijomicin (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>, 16th ed, New York, NY: Medical Letter, 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahkee S, Smith R, and Ritter GW, &ldquo;Once-Daily Aminoglycoside Dosing in Lower Respiratory Tract Infections,&rdquo; <i>Pharm Therapeut</i>, 1995, 20:226-34.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amin NB, Padhi ID, Touchette MA, et al, &ldquo;Characterization of Gentamicin Pharmacokinetics in Patients Hemodialyzed With High-Flux Polysulfone Membranes,&rdquo; <i>Am J Kidney Dis</i>, 1999, 34(2):222-7<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/10430966/pubmed\" target=\"_blank\" id=\"10430966\">10430966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the Treatment of Brucellosis in the 21<sup>st</sup> Century: The Ioannina Recommendations. <i>PLoS Medicine.</i> 2007;12(4):1872-1878.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/18162038/pubmed\" target=\"_blank\" id=\"18162038\">18162038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al. American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended interval dosing versus multiple daily dosing of aminoglycosides. <i>Clin Infect Dis</i>. 1997;24(5):786-795.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/9142771/pubmed\" target=\"_blank\" id=\"9142771\">9142771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt-Mehta V, Johnson CE and Schumacher RE, &ldquo;Gentamicin Pharmacokinetics in Term Neonates Receiving Extracorporeal Membrane Oxygenation,&rdquo; <i>Pharmacotherapy</i>, 1992, 12(1):28-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/1549536/pubmed\" target=\"_blank\" id=\"1549536\">1549536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brummett RE, Bendrick T, and Himes D, &quot;Comparative Ototoxicity of Bumetanide and Furosemide When Used in Combination With Kanamycin,&quot; <i>J Clin Pharmacol</i>, 1981, 21(11-12 Pt 2):628-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/7338574/pubmed\" target=\"_blank\" id=\"7338574\">7338574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Celiloglu M, Celiker S, Guven H, et al, &quot;Gentamicin Excretion and Uptake From Breast Milk by Nursing Infants,&quot; <i>Obstet Gynecol</i>, 1994, 84(2):263-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/8041544/pubmed\" target=\"_blank\" id=\"8041544\">8041544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Recommended antibiotic treatment for plague. Updated October 2015. Available at <a href=\"http://www.cdc.gov/plague/resources/Recommended-antibiotics-for-plague_revision-Aug-2015_Final-(00000002).pdf\" target=\"_blank\">http://www.cdc.gov/plague/resources/Recommended-antibiotics-for-plague_revision-Aug-2015_Final-(00000002).pdf</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/8041544/pubmed\" target=\"_blank\" id=\"8041544\">8041544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow MS, Quintiliani, and Nightingale CH, &quot;<i>In Vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report,&quot; <i>JAMA</i>, 1982, 247(5):658-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/6798229/pubmed\" target=\"_blank\" id=\"6798229\">6798229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al. Extended-interval aminoglycoside administration for children: a meta-Analysis. <i>Pediatrics. </i>2004;114(1):e111-e118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/15231982/pubmed\" target=\"_blank\" id=\"15231982\">15231982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE, King JH. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. <i>Ann Pharmacother.</i> 2006;40:9-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/16332944/pubmed\" target=\"_blank\" id=\"16332944\">16332944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daly JS, Dodge RA, Glew RH, et al, &quot;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,&quot; <i>J Perinatol</i>, 1997, 17(1):42-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/9069064/pubmed\" target=\"_blank\" id=\"9069064\">9069064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Demczar DJ, Nafziger AN, and Bertino JS Jr, &quot;Pharmacokinetics of Gentamicin at Traditional Versus High Doses: Implications for Once-Daily Aminoglycoside Dosing,&quot; <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1115-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/9145878/pubmed\" target=\"_blank\" id=\"9145878\">9145878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. <i>JAMA</i>. 2001;285(21):2763-2773.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/11386933/pubmed\" target=\"_blank\" id=\"11386933\">11386933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell JA, Korth-Bradley J, Milisci M, et al, &quot;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&quot; <i>J Clin Pharmacol</i>, 2001, 41:979-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/11549103/pubmed\" target=\"_blank\" id=\"11549103\">11549103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farchione LA, &quot;Inactivation of Aminoglycosides by Penicillins,&quot; <i>J Antimicrob Chemother</i>, 1982, 8(Suppl A):27-36.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs PC, Stickel S, Anderson PH, et al, &quot;<i>In Vitro</i> Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&quot; <i>Antimicrob Agents Chemother</i>, 1991, 35(1):182-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/2014975/pubmed\" target=\"_blank\" id=\"2014975\">2014975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gentamicin sulfate 40 mg/mL Injection [prescribing information]. Lake Forest, IL: Hospira Inc; August 2005</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gentamicin injection [prescribing information]. Schaumberg, IL: APP Pharmaceuticals LCC; August 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gentamicin pediatric injection [prescribing information]. Lake Zurich, IL: APP Pharmaceuticals LCC; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gentamicin sulfate in 0.99% sodium chloride injection [prescribing information]. Lake Forest, IL: Hospira; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN and Leggett JE, &ldquo;Aminoglycosides,&rdquo; <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases,</i> 7th ed, Chapter 26, Mandell GL, Bennett JE, and Dolin R, eds, Philadelphia, PA: Churchill Linvingstone Elsevier, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN, Moellering RC, Eliopoulos GM, et al, eds, <i>The Sanford Guide To Antimicrobial Therapy</i>, 2006, 36th ed, Hyde Park, VT: Antimicrobial Therapy, Inc, 2006, 6-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN, &ldquo;Once-Daily Aminoglycoside Therapy,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(3):399-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/2039189/pubmed\" target=\"_blank\" id=\"2039189\">2039189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodwin SD, Nix DE, Heyd A, et al, &ldquo;Compatibility of Ciprofloxacin Injection with Selected Drugs and Solutions,&rdquo; <i>Am J Hosp Pharm</i>, 1991, 48(10):2166-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/1781473/pubmed\" target=\"_blank\" id=\"1781473\">1781473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halstenson CE, Wong MO, Herman CS, et al, &quot;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&quot; <i>Antimicrob Agents Chemother</i>, 1992, 36(9):1832-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/1416875/pubmed\" target=\"_blank\" id=\"1416875\">1416875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hilmer SN, Perera V, Mitchell S, et al. The assessment of frailty in older people in acute care. <i>Australas J Ageing</i>. 2009;28(4):182-188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/19951339/pubmed\" target=\"_blank\" id=\"19951339\">19951339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hilmer SN, Tran K, Rubie P, et al. Gentamicin pharmacokinetics in old age and frailty. <i>Br J Clin Pharmacol</i>. 2011;71(2):224-231.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/21219402/pubmed\" target=\"_blank\" id=\"21219402\">21219402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hitt CM, Patel KB, Nicolau DP, et al, &quot;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&quot; <i>Am J Health Syst Pharm</i>, 1997, 54(23):2704-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/9408514/pubmed\" target=\"_blank\" id=\"9408514\">9408514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jolley JA, Wing DA. Pyelonephritis in pregnancy: an update on treatment options for optimal outcomes. <i>Drugs</i>. 2010;70(13):1643-1655.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/20731473 /pubmed\" target=\"_blank\" id=\"20731473 \">20731473 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konishi H, Goto M, Nakamoto Y, et al, &quot;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 23(5):653-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/6223576/pubmed\" target=\"_blank\" id=\"6223576\">6223576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau A, Lee M, Flascha S, et al, &quot;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients with Normal Renal Function,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 24(4):533-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/6651279/pubmed\" target=\"_blank\" id=\"6651279\">6651279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leggett JE. Aminoglycosides. <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.</i> 8th ed, Chapter 25, Bennett JE, Doin R, and Blaser MJ, eds, Philadelphia, PA: Saunders, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27282851\"></a>Li PK, Szeto CC, Piraino B, et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. <i>Perit Dial Int</i>. 2016;36(5):481-508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/27282851/pubmed\" target=\"_blank\" id=\"27282851\">27282851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children. <i>Clin Infect Dis</i>. 2011;52(3):e18-55. doi: 10.1093/cid/ciq146.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/21208910/pubmed\" target=\"_blank\" id=\"21208910\">21208910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucena MI, Andrade RJ, Cabello MR, et al, &ldquo;Aminoglycoside-Associated Nephrotoxicity in Extrahepatic Obstructive Jaundice,&rdquo; <i>J Hepatol</i>, 1995, 22(2):189-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/7790708/pubmed\" target=\"_blank\" id=\"7790708\">7790708</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacDougall C, Chambers HF. Aminoglycosides. <i>Goodman &amp; Gilman&rsquo;s: The Pharmacological Basis of Therapeutics,</i> 12th ed, Chapter 54, Brunton LL, Chabner BA, Knollmann BC, eds. McGraw-Hill, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mann HJ, Fuhs DW, Awang R, et al, &ldquo;Altered Aminoglycoside Pharmacokinetics in Critically Ill Patients With Sepsis,&rdquo; <i>Clin Pharm</i>, 1987, 6(2):148-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/3665367/pubmed\" target=\"_blank\" id=\"3665367\">3665367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matz GJ, &ldquo;Aminoglycoside Ototoxicity,&rdquo; <i>Am J Otolaryngol</i>, 1986, 7(2):117-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/3485932/pubmed\" target=\"_blank\" id=\"3485932\">3485932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matzke GR, Burkle WS, Lucarotti RL. Gentamicin and tobramycin dosing guidelines: an evaluation. <i>Drug Intell Clin Pharm.</i>1983;17(6):425-432.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/6861633/pubmed\" target=\"_blank\" id=\"6861633\">6861633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matzke GR, Jameson JJ, and Halstenson CE, &ldquo;Gentamicin Disposition in Young and Elderly Patients With Various Degrees of Renal Function,&rdquo; <i>J Clin Pharmacol</i>, 1987, 27(3):216-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/3680577/pubmed\" target=\"_blank\" id=\"3680577\">3680577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDade EJ, Wagner JL, Moffett BS, et al. Once-daily gentamicin dosing in pediatric patients without cystic fibrosis. <i>Pharmacotherapy.</i> 2010;30(3):248-253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/20180608/pubmed\" target=\"_blank\" id=\"20180608\">20180608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolau DP, Freeman CD, Belliveau PP, et al, &ldquo;Experience With a Once-Daily Aminoglycoside Program Administered to 2184 Adult Patients,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(3):650-655.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/7793867/pubmed\" target=\"_blank\" id=\"7793867\">7793867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Brien RK and Sparling TG, &ldquo;Gentamicin and Fludarabine Ototoxicity,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(2):200-1.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Popovi&#263; J, Gruji&#263; Z, and Sabo A, &quot;Influence of Pregnancy on Ceftriaxone, Cefazolin and Gentamicin Pharmacokinetics in Caesarean vs. Non-pregnant Sectioned Women,&quot; <i>J Clin Pharm Ther</i>, 2007, 32(6):595-602.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/18021337/pubmed\" target=\"_blank\" id=\"18021337\">18021337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regamey C, Gordon RC, Kirby WM. Comparative pharmacokinetics of tobramycin and gentamicin.<i> Clin Pharmacol Ther. </i>1973;14(3):396-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/4698568/pubmed\" target=\"_blank\" id=\"4698568\">4698568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reimche LD, Rooney, ME, Hindmarsh KW, et al, &ldquo;An Evaluation of Gentamicin Dosing According to Renal Function in Neonates With Suspected Sepsis,&rdquo; <i>Am J Perinatol</i>, 1987, 4(3):262-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/3606761/pubmed\" target=\"_blank\" id=\"3606761\">3606761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russoe ME and Atkins-Thor E, &quot;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,&quot; <i>Clin Nephrol</i>, 1981, 15(4):175-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/7237864/pubmed\" target=\"_blank\" id=\"7237864\">7237864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shevchuk YM and Taylor DM, &ldquo;Aminoglycoside Volume of Distribution in Pediatric Patients,&rdquo; <i>DICP</i>, 1990, 24(3):273-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/2316235/pubmed\" target=\"_blank\" id=\"2316235\">2316235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of <i>America. Surg Infect (Larchmt)</i>. 2010;11(1):79-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/20163262/pubmed\" target=\"_blank\" id=\"20163262\">20163262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith CR and Lietman PS, &quot;Effect of Furosemide on Aminoglycoside-Induced Nephrotoxicity and Auditory Toxicity in Humans,&quot; Antimicrob Agents Chemother, 1983, 23(1):133-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/6830203/pubmed\" target=\"_blank\" id=\"6830203\">6830203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson MIB, Russo ME, Saxon BJ, et al, &quot;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&quot; <i>Antimicrob Agents Chemother</i>, 1982, 21(2):268-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/6462107/pubmed\" target=\"_blank\" id=\"6462107\">6462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Townsend PL, Fink MP, Stein KL, et al, &ldquo;Aminoglycoside Pharmacokinetics: Dosage Requirements and Nephrotoxicity in Trauma Patients,&rdquo; <i>Crit Care Med</i>, 1989, 17(2):154-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/2914447/pubmed\" target=\"_blank\" id=\"2914447\">2914447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Traynor AM, Nafziger AN, and Bertino JS Jr, &ldquo;Aminoglycoside Dosing Weight Correction Factors for Patients of Various Body Sizes,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(2):545-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/7726530/pubmed\" target=\"_blank\" id=\"7726530\">7726530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i> Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viollier AF, Standiford HC, Drusano GL, et al, &quot;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,&quot; <i>J Antimicrob Chemother</i>, 1985, 15(5):597-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/4008387/pubmed\" target=\"_blank\" id=\"4008387\">4008387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; Circulation, 2007, 116(15):1736-54. Available at http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v117446442</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). WHO guidelines on tularemia. 2007. Available at http://whqlibdoc.who.int/publications/2007/9789241547376_eng.pdf. Last accessed: June 23, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics, 2<sup>nd</sup> ed.Spokane, WA: Applied Therapeutics, Inc., 1986, p. 362.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9142 Version 194.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8107079\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8107109\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8107344\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8107267\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8107266\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8107268\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8107269\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8107270\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330558\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8107316\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8107117\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8107276\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8107118\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475908\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8107082\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8107169\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8107166\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8107167\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299397\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8107194\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8107119\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8107120\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8107165\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8107280\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F8107222\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8107220\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8107223\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8107318\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12707701\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9142|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gentamicin-systemic-patient-drug-information\" class=\"drug drug_patient\">Gentamicin (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=gentamicin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Gentamicin (systemic): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}